Close Menu

siRNA

IP Update: Feb 26, 2009

Premium

USPTO Publishes Six RNAi-Related Patent Applications

Thomas Cech, Jeffery Vick

Strands: Feb 26, 2009

Premium

Tekmira Pharmaceuticals, MDRNA

Sylentis will perform the initial clinical trial on its own in Spain for logistical reasons, but expects to later test the topically administered drug in other countries, including the US, according to a company official.

IP Update: Feb 19, 2009

Premium

USPTO Publishes Six RNAi-Related Patent Applications

Strands: Feb 19, 2009

Premium

MDRNA, Roche, Arrowhead Research, Rosetta Genomics, Alnylam Pharmaceuticals, Genesis Research and Development

During a conference call held this week to discuss Arrowhead Research's fiscal first-quarter financial results, President and CEO Christopher Anzalone said that the company was in a position to stay afloat for at least the next nine months.

The researchers evaluated the effects of small molecules in both in vitro enzymatic assays and cell-based assays to develop what they said are the first isoform-selective phospholipase D inhibitors, which are potential antimetastatic agents.

IP Update: Feb 5, 2009

Premium

USPTO Publishes Seven RNAi-Related Patent Applications

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.